HCV and Direct Acting Antivirals: The Dream and the Reality
| 시간 | 일정 | 비고 |
|---|---|---|
| 13:20 ~ 13:40 | 환영사 | 최성규 (광주-전남지회 회장) |
| 격려사 | 이영상 (대한간학회 회장) | |
| Session 1 | HCV-disease burden and clinical implications in Korea | 좌장: 최성규, 이영상 |
| 13:40 ~ 14:00 | HCV epidemiology in Korea: Focused on community based HCV epidemiologic investigation at Jindo-gun | 권순석 (전남의대) |
| 14:00 ~ 14:20 | HCV infection-Screening policy | 김형준 (중앙의대) |
| 14:20 ~ 14:40 | 2015 KASL HCV guideline | 정숙향 (서울의대) |
| 14:40 ~ 15:00 | Treatment target: Would prioritizing treatment be necessary in DAA era? | 김영석 (순천향의대) |
| 15:00 ~ 15:20 | Viral eradication, a flash of hope? Hepatic and extrahepatic morbidity and mortality | 홍건영 (기독병원) |
| 15:20 ~ 15:40 | Coffee break | |
| Session 2 | Practical issues in the era of DAAs | 좌장: 김만우, 변관수 |
| 15:40 ~ 16:00 | DAAs in advanced liver cirrhosis patients | 전충환 (전남의대) |
| 16:00 ~ 16:20 | Resistance associated variation: IS it obstacles to future drug selection? | 박상훈 (한림의대) |
| 16:20 ~ 16:40 | Drug-drug interaction in DAA treatment: Is there an easy way to go? | 조주연 (조선의대) |
| 16:40 ~ 17:00 | IFN and ribavirin in the era of DAAs | 정영걸 (고려의대) |
| 17:00 ~ 17:20 | New targets for DAAs: Are we still waiting for the new commander? | 조은영 (원광의대) |
사전등록마감 : 2016년 02월 18일(목) 오전 09시까지
PC버전에서 등록 가능합니다.